FDA Approves Celltrion Aflibercept Biosimilar: Eydenzelt

October 13, 2025

The FDA has approved Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US.

Real-World Stability Confirmed for Biosimilar Ximluci in Prefilled Syringes

October 09, 2025

Review Identifies Gaps in Evidence on Biosimilar DMARD Use During Pregnancy

October 09, 2025

Global Biosimilars Market Sees Gains in Access and Pipeline Expansion

October 07, 2025

Proposed Aflibercept Biosimilar Shows Comparable Safety, Efficacy in Phase 3 AMD Trial

October 02, 2025

Real-World Data Suggest Long-Term Safety of CT-P13 in IBD, RA

July 2nd 2025

By Deana Ferreri, PhD

Article

The MEGA-J study reveals CT-P13's long-term safety and effectiveness in treating inflammatory bowel disease and rheumatoid arthritis, with minimal adverse reactions.

Biosimilars Rheumatology Roundup: June 2025

July 1st 2025

By Skylar Jeremias

Article

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and real-world efficacy insights.

Adalimumab Double Take: The Unexpected Return to Reference Humira

June 30th 2025

By Skylar Jeremias

Article

About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.

Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial Hurdles

June 29th 2025

By Cameron Santoro

Video

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and rectifying perverse financial incentives within health care contract structures.

The Top 5 Biosimilar Articles for the Week of June 23

June 27th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 23, 2025.

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26th 2025

By Skylar Jeremias

Article

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in Europe and Latin America.

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25th 2025

By Skylar Jeremias

Article

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults.

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24th 2025

By Skylar Jeremias

Article

CT-P39, an omalizumab biosimilar, shows comparable efficacy and safety to the original in treating chronic spontaneous urticaria, enhancing patient access.

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23rd 2025

By Sarfaraz K. Niazi, PhD

Article

The debate over the Biosimilar Red Tape Elimination Act raises critical concerns about FDA standards, physician trust, and patient safety in biosimilars.

Long-Term Durability and Cost-Effectiveness of Adalimumab Biosimilars in Pediatric IBD

June 22nd 2025

By Deana Ferreri, PhD

Article

A real-world study reveals that pediatric patients with IBD achieve high remission rates and cost savings using adalimumab biosimilars over time.